Searchable abstracts of presentations at key conferences in endocrinology

ea0090p511 | Thyroid | ECE2023

Retrospective analysis of diagnostic and therapeutic management in thyroid cancer patients in 2019- 2021 to assess the possibility of treatment de-escalation

Kolton Magdalena , Handkiewicz-Junak Daria , Krajewska Jolanta

Introduction: In recent years, there has been a significant increase in the detection of thyroid cancer (TC) and a number of thyroid surgeries. Both the ATA 2015 and 2022 Polish guidelines allow sparing treatment in low-risk TC, nevertheless, most patients are qualified for total thyroidectomy.Material and method: The present study analyzed how often a TC patient opts for sparing treatment and the relationship between the size of the primary focus and ri...

ea0035p550 | Endocrine tumours and neoplasia | ECE2014

The effectiveness of yttrium90/lutetium177-labeled somatostatin analogues treatment in functional pNETs

Michalik Barbara , Handkiewicz-Junak Daria , Hasse-Lazar Kornelia , Jarzab Barbara

Introduction: Therapy with somatostatin analouges is usually ineffective to remove hormonal symptoms in patients with functional pancreatic neuroendocrine tumors (pNET). Alternative treatment modalities, to control symptoms of excessive hormonal production, are necessary. Thus, the aim of our study was to evaluate results of radiopeptide treatment in patient with functional pNET.Materials and methods: 92 patients with pNET (49 women and 43 men, median ag...

ea0092ps1-01-09 | Cancer | ETA2023

Risk of renal adverse effects in patients with advanced thyroid cancer who are undergoing radiological monitoring, with a particular focus on patients receiving tyrosine kinase inhibitors

Haras-Gil Malgorzata , Samborski Konrad , Ledwon Aleksandra , Kolton Magdalena , Handkiewicz-Junak Daria , Jarzab Barbara , Krajewska Jolanta

Introduction: Systemic treatment of advanced progressing thyroid cancer (TC) is based on molecularly targeted therapy with tyrosine kinase inhibitors (TKIs), mainly inhibitors targeting vascular endothelial growth factor receptors (VEGFR). Such treatment is related to numerous side effects. However, the relationship between TKIs and renal adverse events (RAEs) is unclear. VEGFR inhibitors are associated with proteinuria. In some patients, increased serum creatinine level and t...

ea0099p161 | Thyroid | ECE2024

Differentiated thyroid cancer in pregnancy. A retrospective analysis of newly diagnosed patients

Bulwa Maciej , Samborski Konrad , Kolton Magdalena , Haras-Gil Malgorzata , Jarzab Barbara , Handkiewicz-Junak Daria , Krajewska Jolanta

Introduction: The question of whether pregnancy has any impact on the prognosis of differentiated thyroid cancer diagnosed in pregnant women was addressed mainly in retrospective analyses, which showed no significant differences in overall and progression-free survival between women diagnosed during pregnancy in comparison to women whose thyroid cancer diagnosis was unrelated to pregnancy. Thus, following the recent guidelines, watchful waiting is the preferred option, and sur...

ea0084ps2-10-96 | Nodules & Cancer | ETA2022

Prospective, observational study on radioiodine treatment in DTC patients with intermediate RISK or micro lymph node metastases

Blewaska Aleksandra , Ledwon Aleksandra , Paliczka-Cieslik Ewa , Sygula Aleksandra , Haras-Gil Malgorzata , Kropinska Aleksandra , Czarniecka Agnieszka , Handkiewicz-Junak Daria

There are much controversy adjuvant radioiodine treatment (131-I-th) in intermediate or low risk patients with lymph node micrometastases. The first results of ESTIMABL2 trial showed no radioiodine benefit in low risk DTC, however intermediate patients were not included in this study.Aim: Observational study was to evaluate effects of 131-I-th in intermediate/low risk DTC patients.Patients: There were 342 women (85%), the median ag...

ea0049ep1440 | Thyroid (non-cancer) | ECE2017

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Krajewska Jolanta , Kukulska Aleksandra , Handkiewicz-Junak Daria , Paliczka-Cieslik Ewa , Olczyk Tomasz , Gawlik Tomasz , Ledwon Aleksandra , Michalik Barbara , Jarzab Barbara

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

ea0035oc1.5 | Thyroid clinical | ECE2014

rh-TSH (Thyrogen) aided radioiodine therapy in children and adolescents with DTC

Handkiewicz-Junak Daria , Roskosz Jozef , Gawlik Tomasz , Olczyk Tomasz , Gubala Elzbieta , Kropinska Aleksandra , Hasse-Lazar Kornelia , Jarzab Barbara

Background: Although recombinant human TSH (rhTSH) is widely used to aid radioiodine treatment of differentiated thyroid cancer (DTC), however, there are data on its effectivness in children and adolescents with DTC.The aim of our retrospective study was to evaluate effectiveness and safety of rhTSH aided radioiodine treatment in DTC patients 18 years of age or younger.Material and Methods: Fifty five children/adolescents (median a...

ea0035p562 | Endocrine tumours and neoplasia | ECE2014

Consolidation treatment with somatoatatin analogues after radiopeptide therapy

Sygula Aleksandra , Handkiewicz-Junak Daria , Kotecka-Blicharz Agnieszka , Hasse-Lazar Kornelia , Jurecka-Lubieniecka Beata , Krajewska Jolanta , Jarzab Barbara

Background: Although neuroendocrine tumours (NET) constitute a very heterogeneous group, most of them express somatostatin receptors that enable treatment with somatostatin analogues(SA), which proved to be effective both as bio- or radiopeptide therapy. However, little is now about combining this two treatment modalities.The aim of our prospective study was to evaluate results of radiolabeled somatostatin analogues (PRRT) with or without long lasting ‘cold’ SA as co...

ea0084op-03-13 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Thyroid cancer relapse as a challenge to a surgeon: The efficacy of radioguided occult lesion localization (roll) technique

Czarniecka Agnieszka , Wozniak Grzegorz , Zeman Marcin , Kalemba Michal , Wygoda Zbigniew , Chmielik Ewa , Stobiecka Ewa , J. Cortez Alexander , Krajewska Jolanta , Handkiewicz-Junak Daria

Introduction: Reoperation due to recurrent or persistent thyroid cancer (TC) poses a real challenge to a surgeon who must properly estimate the benefit risk-ratio. Radioguided occult lesion localization (ROLL) technique may facilitate the localization and sufficient and safe removal of nonpalpable TC relapse.Aim: To analyze the efficacy of the ROLL technique in reoperation of TC relapse.Material and methods: A retrospective study o...

ea0037ep904 | Thyroid cancer | ECE2015

Adjuvant radioiodine (RAI) treatment reduces the risk of relapse in low advanced differentiated thyroid carcinoma (DTC)

Krajewska Jolanta , Jarzab Michal , Czarniecka Agnieszka , Kukulska Aleksandra , Handkiewicz-Junak Daria , Wygoda Zbigniew , Puch Zbigniew , Paliczka-Cieslik Ewa , Roskosz Jozef , Jarzab Barbara

The routine use of adjuvant RAI treatment in low-risk DTC remains controversial due to the lack of unequivocal evidences of its effectiveness in radically operated subjects. The aim of the study was a retrospective evaluation of long-term outcomes of combined DTC treatment to evaluate the impact of adjuvant RAI therapy in the low risk group. Primary hypothesis was: ‘if adjuvant RAI treatment was unnecessary, a delay in RAI administration would have no impact on long-term ...